|
|
|
|
Lux
Biosciences to Present at JERSEY CITY, N.J., March 8, 2007 — Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that A. Clarke Atwell, Chief Operating Officer, will present a company overview at the Cowen & Company 27th Annual Health Care Conference in Boston. The presentation will take place at 5:30 pm ET on Wednesday, March 14th, 2007, at The Boston Marriott Copley Place Hotel. About Lux BiosciencesLux Biosciences is a privately held biotechnology company dedicated to the identification, optimization, development and commercialization of products for the treatment of ophthalmic diseases. The company's business strategy is characterized by: ● A focus on compounds already marketed or with clinical proof-of-concept in non-ophthalmic indications that Lux Biosciences will develop as unique, targeted therapies for corresponding ophthalmic diseases, with potentially greater efficacy and safety than existing treatments. ● A clinical-stage portfolio of projects including: i) a next-generation calcineurin inhibitor that has potential in several ophthalmic diseases and, as such, represents a pipeline of product opportunities; and ii) a silicone matrix ocular implant that steadily releases therapeutic doses of cyclosporine A locally to the eye. The LUMINATE pivotal clinical studies of Lux Biosciences’ next generation calcineurin inhibitor, LX211 for the treatment of uveitis, were initiated in February 2007 and pivotal studies of the cyclosporine A implant, LX201 for the prevention of corneal transplant rejection, are expected to start around the end of Q1, 2007. ● A proprietary product-enabling bio-erodible polymer technology that allows targeted and sustained delivery of molecules to the eye. For more information on Lux Biosciences, please visit the company’s website at www.luxbio.com.
### CONTACTS
Lux
Biosciences, Inc.
|
© 2008 Lux Biosciences, Inc. All rights reserved. Web Terms
